Flossbach Von Storch SE reduced its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 3.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 379,735 shares of the medical technology company's stock after selling 14,931 shares during the period. Flossbach Von Storch SE owned about 0.10% of Stryker worth $141,356,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in SYK. Capital A Wealth Management LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $26,000. Rakuten Securities Inc. raised its holdings in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after buying an additional 68 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Stryker in the 1st quarter valued at about $32,000. City Holding Co. boosted its stake in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the last quarter. Finally, VSM Wealth Advisory LLC bought a new stake in Stryker during the 4th quarter worth approximately $36,000. 77.09% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
SYK has been the topic of a number of recent research reports. BTIG Research set a $403.00 price target on Stryker and gave the company a "buy" rating in a research report on Monday, April 14th. Truist Financial raised their price target on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research note on Monday, May 5th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Finally, Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and an average price target of $428.55.
View Our Latest Analysis on SYK
Insider Buying and Selling
In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.90% of the company's stock.
Stryker Price Performance
Shares of SYK traded up $3.66 during trading hours on Thursday, hitting $395.71. The stock had a trading volume of 286,161 shares, compared to its average volume of 1,459,413. The company's fifty day moving average is $384.17 and its two-hundred day moving average is $376.78. Stryker Corporation has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market capitalization of $151.04 billion, a price-to-earnings ratio of 53.47, a P/E/G ratio of 2.94 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00.
Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the firm earned $2.50 earnings per share. The business's quarterly revenue was up 11.9% on a year-over-year basis. On average, analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.
Stryker Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.85%. Stryker's dividend payout ratio (DPR) is presently 45.41%.
Stryker Company Profile
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
